286 related articles for article (PubMed ID: 23056595)
1. Novel agents targeting the IGF-1R/PI3K pathway impair cell proliferation and survival in subsets of medulloblastoma and neuroblastoma.
Wojtalla A; Salm F; Christiansen DG; Cremona T; Cwiek P; Shalaby T; Gross N; Grotzer MA; Arcaro A
PLoS One; 2012; 7(10):e47109. PubMed ID: 23056595
[TBL] [Abstract][Full Text] [Related]
2. Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibody.
Chapuis N; Tamburini J; Cornillet-Lefebvre P; Gillot L; Bardet V; Willems L; Park S; Green AS; Ifrah N; Dreyfus F; Mayeux P; Lacombe C; Bouscary D
Haematologica; 2010 Mar; 95(3):415-23. PubMed ID: 20007139
[TBL] [Abstract][Full Text] [Related]
3. R1507, an anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, and EWS/FLI-1 siRNA in Ewing's sarcoma: convergence at the IGF/IGFR/Akt axis.
Huang HJ; Angelo LS; Rodon J; Sun M; Kuenkele KP; Parsons HA; Trent JC; Kurzrock R
PLoS One; 2011; 6(10):e26060. PubMed ID: 22022506
[TBL] [Abstract][Full Text] [Related]
4. Quantitative phosphoproteomic analysis identifies activation of the RET and IGF-1R/IR signaling pathways in neuroblastoma.
DeNardo BD; Holloway MP; Ji Q; Nguyen KT; Cheng Y; Valentine MB; Salomon A; Altura RA
PLoS One; 2013; 8(12):e82513. PubMed ID: 24349301
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of IGF-1R-dependent PI3K activation sensitizes colon cancer cells specifically to DR5-mediated apoptosis but not to rhTRAIL.
Pennarun B; Kleibeuker JH; Oenema T; Stegehuis JH; de Vries EG; de Jong S
Cell Oncol (Dordr); 2011 Jun; 34(3):245-59. PubMed ID: 21538027
[TBL] [Abstract][Full Text] [Related]
6. R1507, a fully human monoclonal antibody targeting IGF-1R, is effective alone and in combination with rapamycin in inhibiting growth of osteosarcoma xenografts.
Kolb EA; Kamara D; Zhang W; Lin J; Hingorani P; Baker L; Houghton P; Gorlick R
Pediatr Blood Cancer; 2010 Jul; 55(1):67-75. PubMed ID: 20486173
[TBL] [Abstract][Full Text] [Related]
7. IGF-1R targeting increases the antitumor effects of DNA-damaging agents in SCLC model: an opportunity to increase the efficacy of standard therapy.
Ferté C; Loriot Y; Clémenson C; Commo F; Gombos A; Bibault JE; Fumagalli I; Hamama S; Auger N; Lahon B; Chargari C; Calderaro J; Soria JC; Deutsch E
Mol Cancer Ther; 2013 Jul; 12(7):1213-22. PubMed ID: 23640142
[TBL] [Abstract][Full Text] [Related]
8. Synergy between an IGF-1R antibody and Raf/MEK/ERK and PI3K/Akt/mTOR pathway inhibitors in suppressing IGF-1R-mediated growth in hematopoietic cells.
Bertrand FE; Steelman LS; Chappell WH; Abrams SL; Shelton JG; White ER; Ludwig DL; McCubrey JA
Leukemia; 2006 Jul; 20(7):1254-60. PubMed ID: 16642049
[TBL] [Abstract][Full Text] [Related]
9. Dependence on PI3K/Akt signaling for malignant rhabdoid tumor cell survival.
Foster K; Wang Y; Zhou D; Wright C
Cancer Chemother Pharmacol; 2009 Apr; 63(5):783-91. PubMed ID: 18641990
[TBL] [Abstract][Full Text] [Related]
10. Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma.
Desbois-Mouthon C; Baron A; Blivet-Van Eggelpoël MJ; Fartoux L; Venot C; Bladt F; Housset C; Rosmorduc O
Clin Cancer Res; 2009 Sep; 15(17):5445-56. PubMed ID: 19706799
[TBL] [Abstract][Full Text] [Related]
11. Insulin growth factor 1 receptor/PI3K/AKT survival pathway in outer segment membranes of rod photoreceptors.
Dilly AK; Rajala RV
Invest Ophthalmol Vis Sci; 2008 Nov; 49(11):4765-73. PubMed ID: 18566464
[TBL] [Abstract][Full Text] [Related]
12. Selective inhibition of SCLC growth by the A12 anti-IGF-1R monoclonal antibody correlates with inhibition of Akt.
Yeh J; Litz J; Hauck P; Ludwig DL; Krystal GW
Lung Cancer; 2008 May; 60(2):166-74. PubMed ID: 18006183
[TBL] [Abstract][Full Text] [Related]
13. Tanshinone I inhibits vascular smooth muscle cell proliferation by targeting insulin-like growth factor-1 receptor/phosphatidylinositol-3-kinase signaling pathway.
Wu YT; Bi YM; Tan ZB; Xie LP; Xu HL; Fan HJ; Chen HM; Li J; Liu B; Zhou YC
Eur J Pharmacol; 2019 Jun; 853():93-102. PubMed ID: 30878387
[TBL] [Abstract][Full Text] [Related]
14. Antitumor effects and molecular mechanisms of figitumumab, a humanized monoclonal antibody to IGF-1 receptor, in esophageal carcinoma.
Zhang T; Shen H; Dong W; Qu X; Liu Q; Du J
Sci Rep; 2014 Oct; 4():6855. PubMed ID: 25358597
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of IGF-1R-dependent PI3K activation sensitizes colon cancer cells specifically to DR5-mediated apoptosis but not to rhTRAIL.
Pennarun B; Kleibeuker JH; Oenema T; Stegehuis JH; de Vries EG; de Jong S
Anal Cell Pathol (Amst); 2010; 33(5):229-44. PubMed ID: 20978316
[TBL] [Abstract][Full Text] [Related]
16. Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions.
Liu B; Fan Z; Edgerton SM; Yang X; Lind SE; Thor AD
Cell Cycle; 2011 Sep; 10(17):2959-66. PubMed ID: 21862872
[TBL] [Abstract][Full Text] [Related]
17. Heterogeneity of neuroblastoma cell lines in insulin-like growth factor 1 receptor/Akt pathway-mediated cell proliferative responses.
Qi L; Toyoda H; Shankar V; Sakurai N; Amano K; Kihira K; Iwasa T; Deguchi T; Hori H; Azuma E; Gabazza EC; Komada Y
Cancer Sci; 2013 Sep; 104(9):1162-71. PubMed ID: 23710710
[TBL] [Abstract][Full Text] [Related]
18. Detection of PI3K inhibition in human neuroblastoma using multiplex luminex bead immunoassay: a targeted approach for pathway analysis.
Lang WH; Sandoval JA
J Biomol Screen; 2014 Oct; 19(9):1235-45. PubMed ID: 25092063
[TBL] [Abstract][Full Text] [Related]
19. Interruption of mitochondrial complex IV activity and cytochrome c expression activated O₂·⁻-mediated cell survival in silibinin-treated human melanoma A375-S2 cells via IGF-1R-PI3K-Akt and IGF-1R-PLC γ-PKC pathways.
Jiang YY; Huang H; Wang HJ; Wu D; Yang R; Tashiro S; Onodera S; Ikejima T
Eur J Pharmacol; 2011 Oct; 668(1-2):78-87. PubMed ID: 21703257
[TBL] [Abstract][Full Text] [Related]
20. The insulin-like growth factor-I receptor kinase inhibitor NVP-ADW742 sensitizes medulloblastoma to the effects of chemotherapy.
Zhou H; Rao J; Lin J; Yin B; Sheng H; Lin F; Zhang N; Yang L
Oncol Rep; 2011 Jun; 25(6):1565-71. PubMed ID: 21455580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]